TTNP — Titan Pharmaceuticals Balance Sheet
0.000.00%
- $3.43m
- $0.60m
- 28
- 25
- 38
- 20
Annual balance sheet for Titan Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 5.41 | 6.04 | 2.94 | 6.76 | 2.83 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.884 | 0.112 | 0.036 | 1.05 | 0.062 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 7.33 | 7.23 | 3.6 | 8.02 | 2.92 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.759 | 0.717 | 0.407 | 0.068 | 0 |
Other Long Term Assets | |||||
Total Assets | 8.09 | 7.99 | 4.06 | 8.09 | 2.92 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.22 | 2.67 | 2.63 | 1.44 | 0.483 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 4.55 | 2.86 | 2.69 | 1.44 | 0.483 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 3.53 | 5.14 | 1.36 | 6.64 | 2.44 |
Total Liabilities & Shareholders' Equity | 8.09 | 7.99 | 4.06 | 8.09 | 2.92 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |